Cargando…

Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma

PURPOSE: Multiple myeloma (MM) remains an incurable hematologic malignancy which ultimately develops drug resistance and evades treatment. Despite substantial therapeutic advances over the past years, the clinical failure rate of preclinically promising anti-MM drugs remains substantial. More realis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Waldschmidt, Johannes M., Fruttiger, Stefan J., Wider, Dagmar, Jung, Johannes, Thomsen, Andreas R., Hartmann, Tanja N., Duyster, Justus, Hug, Martin J., Azab, Kareem A., Jung, Manfred, Wäsch, Ralph, Engelhardt, Monika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article – Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016043/ https://www.ncbi.nlm.nih.gov/pubmed/35072775 http://dx.doi.org/10.1007/s00432-021-03854-6

Ejemplares similares

Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients
por: Riebl, Veronika, et al.
Publicado: (2021)

Proteasome inhibition: the dawn of novel therapies in multiple myeloma
por: Engelhardt, Monika, et al.
Publicado: (2022)

Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma
por: Dold, Sandra Maria, et al.
Publicado: (2020)

Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo
por: Schnerch, Dominik, et al.
Publicado: (2017)

Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab
por: Strüßmann, Tim, et al.
Publicado: (2022)

Intratibial Injection of Human Multiple Myeloma Cells in NOD/SCID IL-2Rγ(Null) Mice Mimics Human Myeloma and Serves as a Valuable Tool for the Development of Anticancer Strategies
por: Schueler, Julia, et al.
Publicado: (2013)

In search of the optimal proteosome inhibitor. How, when and for whom?
por: Engelhardt, Monika, et al.
Publicado: (2021)

Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life
por: Greil, Christine, et al.
Publicado: (2019)

Validation of the Revised Myeloma Comorbidity Index and other comorbidity scores in a multicenter German study group multiple myeloma trial
por: Dold, Sandra Maria, et al.
Publicado: (2020)

Allogeneic Stem Cell Transplantation in Multiple Myeloma
por: Greil, Christine, et al.
Publicado: (2021)

Suppression of APC/C(Cdh1) has subtype specific biological effects in acute myeloid leukemia
por: Ewerth, Daniel, et al.
Publicado: (2016)

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
por: Shoumariyeh, Khalid, et al.
Publicado: (2021)

Multidisciplinary tumor board analysis: validation study of a central tool in tumor centers
por: Frank, Benedikt, et al.
Publicado: (2022)

Molecularly Targeted Therapies in Multiple Myeloma
por: de la Puente, Pilar, et al.
Publicado: (2014)

Geriatric assessments and frailty scores in multiple myeloma patients: a needed tool for individualized treatment?
por: Möller, Mandy-Deborah, et al.
Publicado: (2021)

Two cases of carfilzomib‐induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma
por: Rassner, Michael, et al.
Publicado: (2021)

Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis
por: Wäsch, Ralph, et al.
Publicado: (2023)

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
por: Muz, Barbara, et al.
Publicado: (2017)

The impact of pulmonary function in patients undergoing autologous stem cell transplantation
por: Duque-Afonso, Jesús, et al.
Publicado: (2021)

Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM–comorbidity score
por: Kleber, M, et al.
Publicado: (2011)

Biological Insights into Myeloma and Other B Cell Malignancies
por: Fulciniti, Mariateresa, et al.
Publicado: (2016)

Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis
por: Rettig, Andrés R., et al.
Publicado: (2021)

Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors
por: Gengenbach, Laura, et al.
Publicado: (2021)

Correction to: Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
por: Greil, C., et al.
Publicado: (2021)

Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
por: Greil, C., et al.
Publicado: (2020)

Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age
por: Engelhardt, Monika, et al.
Publicado: (2020)

Novel immunotherapies in multiple myeloma – chances and challenges
por: Rasche, Leo, et al.
Publicado: (2021)

Spotlight on ixazomib: potential in the treatment of multiple myeloma
por: Muz, Barbara, et al.
Publicado: (2016)

An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence
por: Holler, Maximilian, et al.
Publicado: (2022)

European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma
por: Bruno, Benedetto, et al.
Publicado: (2021)

A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
por: Engelhardt, Monika, et al.
Publicado: (2017)

A Propagated Skeleton Approach to High Throughput Screening of Neurite Outgrowth for In Vitro Parkinson’s Disease Modelling
por: Schikora, Justus, et al.
Publicado: (2021)

The Role of the APC/C and Its Coactivators Cdh1 and Cdc20 in Cancer Development and Therapy
por: Greil, Christine, et al.
Publicado: (2022)

E-selectin-targeting lipid nanoparticles improve therapeutic efficacy and reduce side effects of bortezomib in multiple myeloma
por: Maksimos, Mina, et al.
Publicado: (2023)

Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenarians
por: Dieterle, Martin Philipp, et al.
Publicado: (2023)

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib
por: Muz, Barbara, et al.
Publicado: (2015)

Propagation of spontaneous electrical activity in the ex vivo human uterus
por: Kuijsters, Nienke P.M., et al.
Publicado: (2020)

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
por: Gay, Francesca, et al.
Publicado: (2018)

Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
por: Keppler-Hafkemeyer, Andrea, et al.
Publicado: (2022)

Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
por: Alhallak, Kinan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jna94qk3jgrn2ngohunntrro85